1 in 6 cancer cases are missed after biopsy due to the limitations of 2D histology, which only analyzes around 2% of a tissue sample. This leads to up to 20% false negatives, delayed treatment, and reduced survival rates. Manual, labor-intensive diagnostics also increase workload and healthcare costs, with error rates driving up repeat testing and long-term patient risks.
IMAI MedTech transforms cancer diagnostics with an automated 3D histology platform that provides complete, high-resolution tissue analysis. By capturing 100% of biopsy data and reducing false negatives to as low as 1%, it enables faster, more accurate cancer detection while minimizing human error and manual workload by up to 60%.
Pilots: Partnerships with University of Zurich, University Hospital Zurich
Maturity: TRL 5 – Late prototype phase
Capital raised: 1.45M€
Valuation: 10M€
Open Round: Yes
The system combines robotics, proprietary staining protocols, and AI-driven 3D tissue analysis software. It delivers full biopsy visualization and cell-level statistics within 48 hours. The platform integrates seamlessly into pathology labs and is offered via device sales or leasing, per-use fees, software subscriptions, and IP licensing. Clinical validation and CE/FDA certifications are currently in progress.
Sector: Health Tech
Country: Switzerland
Team: 5
